« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 121, Issue 3
, Pages
785-786
, March 2008
Delayed allergic reactions to omalizumab: Are patients reporting all cases?
-
Patient 5 hours after first dose of omalizumab (left) and 3 days afterwards following treatment (right).
Patient 5 hours after first dose of omalizumab (left) and 3 days afterwards following treatment (right).
Disclosure of potential conflict of interest: T. M. O'Connor has received research support from AstraZeneca. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(08)00129-2
doi: 10.1016/j.jaci.2007.12.1184
© 2008 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 121, Issue 3
, Pages
785-786
, March 2008
